EZH2 and diffuse large B-cell lymphoma: Although these compounds have been shown to specifically degrade EZH2 in a few malignancies like triple negative breast cancer [26, 27] and diffuse large B cell lymphoma [25], few report has indicated their effectiveness in ENKTL.